MMRF PRESS RELEASES
Multiple Myeloma Research Foundation (MMRF) Race for Research Inspires Hope
Hundreds of Patients, Caregivers, and Health Professionals Unite for Cancer
National Harbor, MD and Norwalk, CT — November 12, 2013
On Saturday, November 16, more than 900 patient, caregivers, and health care professionals will gather at the National Plaza to take part in the Multiple Myeloma Research Foundation (MMRF) Race for Research: Washington, D.C. 5K Walk/Run. Honorary Chair of the event is Dr. Dipti Patel-Donnelly with the Virginia Cancer Specialists. Dr. Patel-Donnelly, also Co-Director of the Fairfax Stem Cell Transplant Program, will kick-off opening ceremonies at 9:00am. This family friendly 5K walk/run raises both awareness and funds for multiple myeloma research.
“The MMRF is an organization that is unprecedented in its ability and proven success in bringing together a vast network of physicians, patients, and researchers to achieve some common goals – to pursue innovative means that accelerate the development of next-generation multiple myeloma treatments, to extend the lives of patients, and to ultimately find a cure,” said Dr. Patel-Donnelly. “With the help of supporters and world class partners, the MMRF has built one of the strongest and most impressive cancer communities in the country.”
The MMRF Race for Research Series is held annually in nine cities across the country. Millennium: The Takeda Oncology Company is the national presenting sponsor of the program. Participation in these events offers an opportunity for camaraderie and knowledge sharing for patients, patient family members and friends, members of the myeloma community.
“The MMRF Race for Research program allows myeloma patients and family to proactively make a difference in accelerating new treatments and a cure for this disease,” said Allie Otto, MMRF Race for Research Manager. “The funds raised will help to extend patient lives and truly impact the fight against cancer. Each participant is making an incredibly powerful and important contribution to the urgent work of the MMRF.”
The MMRF is a leading cancer-research foundation that has helped to double survival for multiple myeloma patients since its inception. Together with its partners in the pharmaceutical industry and at academic centers, the MMRF has contributed to the development of six new treatments in the last decade, several of which may be effective in treating other cancers. The MMRF continues to build innovative collaborative models that will accelerate the development of new and better treatments for multiple myeloma and all cancer patients, and lead to cures.
About Multiple Myeloma
Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 41 percent, one of the lowest of all cancers. In 2013, more than 20,000 adults in the United States will be diagnosed with multiple myeloma and nearly 11,000 people are predicted to die from the disease.
About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $225 million since its inception and directs 90% of total budget to research and related programming. As a result, the MMRF has been awarded Charity Navigator’s coveted four-star rating for 10 consecutive years, the highest designation for outstanding fiscal responsibility and exceptional efficiency. For more information about the MMRF, please visit: www.themmrf.org.